Tocqueville Asset Management L.P. lifted its holdings in Voyager Therapeutics Inc (NASDAQ:VYGR) by 25.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,655 shares of the company’s stock after purchasing an additional 5,830 shares during the quarter. Tocqueville Asset Management L.P. owned 0.08% of Voyager Therapeutics worth $493,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in shares of Voyager Therapeutics in the second quarter worth $27,000. Allianz Asset Management GmbH boosted its stake in Voyager Therapeutics by 16.5% during the second quarter. Allianz Asset Management GmbH now owns 93,948 shares of the company’s stock valued at $2,054,000 after buying an additional 13,339 shares in the last quarter. HM Payson & Co. bought a new position in Voyager Therapeutics during the second quarter valued at about $63,000. Bailard Inc. bought a new position in Voyager Therapeutics during the second quarter valued at about $1,116,000. Finally, JPMorgan Chase & Co. boosted its stake in Voyager Therapeutics by 28.0% during the second quarter. JPMorgan Chase & Co. now owns 326,643 shares of the company’s stock valued at $8,590,000 after buying an additional 71,451 shares in the last quarter. 78.63% of the stock is owned by institutional investors.
Several research analysts recently weighed in on VYGR shares. Nomura reaffirmed a “buy” rating and set a $37.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 13th. Cowen reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Voyager Therapeutics in a research note on Monday, August 12th. BidaskClub cut Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 27th. Finally, Morgan Stanley decreased their target price on Voyager Therapeutics from $28.00 to $26.00 and set an “equal weight” rating for the company in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $27.63.
Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Wednesday, November 6th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.42. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. The business had revenue of $20.43 million during the quarter, compared to the consensus estimate of $3.94 million. Research analysts anticipate that Voyager Therapeutics Inc will post -1.95 earnings per share for the current fiscal year.
Voyager Therapeutics Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Featured Article: How do CD ladders protect against rising interest rates?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.